Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Palestine Health Report.
Press releases published on September 3, 2025
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
GlobeNewswire
·
September 3, 2025
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with …
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
GlobeNewswire
·
September 3, 2025
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité …
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
GlobeNewswire
·
September 3, 2025
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and commercialization in the US and …
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected
GlobeNewswire
·
September 3, 2025
LOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today provided an update regarding …
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
GlobeNewswire
·
September 3, 2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), …